Piperacillin + tazobactam

Hypersensitivity to piperacillin, tazobactam, or any other penicillin-antibacterial agent. History of acute severe allergic reaction to any other β-lactam active substances (e.g. cephalosporin, monobactam or carbapenem).

Patient w/ cystic fibrosis, history of seizure disorder. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Assess hematopoietic function periodically. Perform periodic electrolyte determinations in patients w/ low K reserves. Monitor creatinine, BUN, CBC w/ differential, prothrombin time, partial thromboplastin time, LFTs, urinalysis, signs of bleeding, signs of anaphylaxis during 1st dose.

GI effects (e.g. diarrhoea, nausea, constipation), rash (maculopapular, bullous, urticarial, eczemoid), pruritus, fever, headache, insomnia; adverse reactions at inj site (phlebitis, pain, inflammation, thrombophlebitis, oedema). Decreases in Hb and haematocrit, thrombocytopenia, increases in platelet count, transient eosinophilia, leucopenia, neutropenia; positive Coombs' test results, prolonged prothrombin time and partial thromboplastin time. Increases in serum concentrations of creatinine and BUN, changes in serum electrolytes, transient increases in AST, ALT, alkaline phosphatase and bilirubin.
Potentially Fatal: Serious, anaphylactic reactions, antibiotic-induced pseudomembranous colitis, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Interacts w/ high doses of heparin, oral anticoagulants or other drugs that affect blood coagulation or thrombocyte function. Prolongs the neuromuscular blockade of vecuronium and non-depolarising muscle relaxants. Prolongs half-lives w/ probenecid. Increased risk of methotrexate toxicity.

Penicillins

J01CA12 - piperacillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections.
J01CG02 - tazobactam ; Belongs to the class of beta-lactamase inhibitors. Used in the systemic treatment of infections.